Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 2, 2002 - Issue 4
Submit an article Journal homepage
89
Views
3
CrossRef citations to date
0
Altmetric
Drug Evaluation

Modafinil: past, present and future

Christos A Ballas 3535 Market St., 2nd Floor, Philadelphia, PA 19194, USA. [email protected]
,
Deborah Kim 3535 Market St., 2nd Floor, Philadelphia, PA 19194, USA. [email protected]
,
Claudia F Baldassano 3535 Market St., 2nd Floor, Philadelphia, PA 19194, USA. [email protected]
&
Nicholas Hoeh 3535 Market St., 2nd Floor, Philadelphia, PA 19194, USA. [email protected]
Pages 449-457 | Published online: 10 Jan 2014

References

  • Saletu B, Frey R, Krupka M, Anderer P, Grunberger J, Barbanoj MJ. Differential effects of a new central adrenergic agonist-modafinil- and d-amphetamine on sleep and early morning behaviour in young healthy volunteers. Int. J. Gun. Pharmacol. Res. 9(3), 183–195 (1989).
  • Wong YN, Simcoe D, Hartman LN eta]. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J. Gun. Pharmacol. 39(1), 30–40 (1999).
  • Wong YN, King SP, Simcoe D et al. Open- label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J. Gun. Pharmacol. 39(3), 281–288 (1999).
  • Robertson P Jr, Hellriegel ET, Arora S, Nelson M. Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers. Gun. Pharmacol. Ther. 71(1), 46–56 (2002).
  • Robertson P, DeCory 1111, Madan A, Parkinson A. hi vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab. Dispos. 28(6), 664–671 (2000).
  • Robertson P, Jr, Hellriegel ET, Arora S, Nelson M. Effect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers. J. Orin. Phatmacol. 42(2), 205–214 (2002).
  • Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc. Natl Acad. Sci. USA 93,14128–14133 (1996).
  • Scammell TE, Estabrooke IV, McCarthy MT et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J. Neurasci. 20,8620–8628 (2000).
  • Saper CB, Chou TC, Scamme11TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trench Neurosci. 24(12), 726–731 (2001).
  • Scammell TE, Estabrooke IV, McCarthy MT et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J. Neutusci. 20,8620–8628 (2000).
  • Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. Dopaminergic role in stimulant-induced wakefulness. J. Neumsd 21(5), 1787–1794 (2001).
  • Ferraro L, Tanganelli S, Fuxe K eta]. Modafinil does not affect serotonin efflux from rat frontal cortex synaptosomes: comparison with known serotoninergic drugs. Brain Res. 894,307–310 (2001).
  • Ferraro L, Tanganelli S, O'Connor WT, Antonelli T, Rambert F, Fuxe K. The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. Eur Pharmacol. 306(1-3), 33–39 (1996).
  • Simon P, Hemet C, Ramassamy C, Costentin J. Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice. Eur. Neumpsychopharmacol. 5(4), 509–514 (1995).
  • Engber TM, Dennis SA, Jones BE, Miller MS, Contreras PC. Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: comparison with amphetamine. Neumscience 87(4), 905–911 (1998).
  • Ferraro L, Antonelli T, Tanganelli S eta]. The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade. Neumpsychopharmacology 20 (4), 346–356 (1999).
  • Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert F, Fuxe K. The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus. Neurodport 8 (13), 2883–2887 (1997).
  • Brun J, Chamba G, Khalfallah Y et a/. Effect of modafinil on plasma melatonin, cortisol and growth hormone rhythms, rectal temperature and performance in healthy subjects during a 36 h sleep deprivation. Sleep Res. 7 (2), 105–114 (1998).
  • Bourdon L, Jacobs I, Bateman WA, Vallerand AL. Effect of modafinil on heat production and regulation of body temperatures in cold-exposed humans. Aviat. Space Environ. Med 65(11), 999–1004 (1994).
  • Duteil J, Rambert FA, Pessonnier J, Hermant JF, Gombert R, Assous E. Central alpha 1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil; studies with experimental animals. Eur.j Pharmacol 180(1), 49–58 (1990).
  • Ferraro L, Fuxe K, Tanganelli S, Fernandez M, Rambert FA, Antonelli T Amplification of cortical serotonin release: a further neurochemical action of the vigilance-promoting drug modafmil. Aiumphatmacology 39(11), 1974–1983 (2000).
  • Littner M, Johnson SF, McCall WV et al Standards of Practice Committee. Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep 24(4), 451–466 (2001).
  • Anonymous. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Neurology54 (5), 1166–1175 (2000).
  • •This trial against placebo demonstrates the efficacy of modafinil.
  • Anonymous. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. Ann. Neurology 43 (1), 88–97 (1998) .
  • Broughton RJ, Fleming JA, George CF etal. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 49(2), 444–451 (1997).
  • Resset A, Chetrit M, Carlander B, Billiard M. Use of modafinil in the treatment of narcolepsy: a long term follow-up study. Neutvphysiologie Clinique26(1), 60–66 (1996).
  • Mitler MM, Harsh J, Hirshkowitz M, Guilleminault C. Long-term efficacy and safety of modafinil (PROVIGILO) for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep Med 1, 231–243 (2000).
  • Beusterien KM, Rogers AE, Walsleben JA et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep22(6), 757–765 (1999).
  • Guilleminault C, Pelayo R. Narcolepsy in children: a practical guide to its diagnosis, treatment and follow-up. Paediatz: Drugs 2(1), 1–9 (2000).
  • Guilleminault C, Aftab FA, Karadeniz D, Philip P, Leger D. Problems associated with switch to modafinil - a novel alerting agent in narcolepsy. Eur. J. Neurology 7(4), 381–384 (2000).
  • Grozinger M, Hartter S, Hiemke C, Griese EU, Roschke J. Interaction of modafinil and clomipramine as comedication in a narcoleptic patient. Gun. Neuropharmacol 21(2), 127–129 (1998).
  • Bastuji H, Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Frog: Neuropsychopharmacol Biol. Psychiatry 12(5), 695–700 (1988).
  • Bassetti C. Narcolepsy. Cutr Treat. Options Neural 1(4), 291–298 (1999).
  • Guilleminault C, Pelayo R. Narcolepsy in children: a practical guide to its diagnosis, treatment and follow-up. Paediatz: Drugs 2(1), 1–9 (2000).
  • Wong YN, Simcoe D, Hartman LN et a/. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J. Gun. Phatmacol 39(1), 30–40 (1999).
  • Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J. Psychopharmacol 14(1), 53–60 (2000).
  • •This study concerns modafinil's abuse potential.
  • Gold LH, Balster RL. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. PTchopharmacology (e11)126 (4), 286–292 (1996).
  • Anonymous. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Neurology 54 (5), 1166–1175 (2000).
  • Bastuji H, Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Frog: Neuropsychopharmacol Biol. Bychiatry 12(5), 695–700 (1988).
  • Besset A, Chetrit M, Carlander B, Billiard M. Use of modafinil in the treatment of narcolepsy: a long term follow-up study. Neurophysiologie Clinique 26(1), 60–66 (1996).
  • Jasinski DR, Kovacevic-Ristanovic R. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Gun. Neuropharmacol 23(3), 149–156 (2000).
  • Caldwell JA Jr, Caldwell JL, Smythe NK 3rd, Hall KIK. A double-blind, placebo-controlled investigation of the efficacy of modafinil for sustaining the alertness and performance of aviators: a helicopter simulator study. PTchophatmacology (Berl.) 150(3), 272–282 (2000).
  • Pigeau R, Naitoh P, Buguet A et al. Modafinil, D-amphetamine and placebo during 64 hours of sustained mental work. I. Effects on mood, fatigue, cognitive performance and body temperature. I Sleep Res. 4(4), 212–228 (1995). Shows the efficacy of modafinil and compares it with a known standard.
  • Batejat DM, I .agarde DR Naps and modafinil as countermeasures for the effects of sleep deprivation on cognitive performance. Aviat. Space Environ. Med 70(5), 493–498 (1999).
  • Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil((R))) for the treatment of fatigue in multiple sclerosis: a two centre Phase 2 study. I Neural Neurosurg. Psychiatry 72(2), 179–183 (2002).
  • Damian MS, Gerlach A, Schmidt F, Lehmann E, Reichmann H. Modafinil for excessive daytime sleepiness in myotonic dystrophy. Neurology 56(6), 794–796 (2001).
  • Jenner P, Zeng BY, Smith LA et al Antiparkinsonian and neuroprotective effects of modafinil in the MPTP-treated common marmoset. Exp. Brain Res. 133(2), 178–188 (2000).
  • Ueki A, Rosen L, Andbjer B et al The vigilance-promoting drug modafinil counteracts the reduction of tyrosine hydroxylase immunoreactivity and of dopamine stores in nigrostriatal dopamine neurons in the male rat after a partial transection of the dopamine pathway. Exp. Brain Res. 93(2), 259–270 (1993).
  • Fuxe K, Janson AM, Rosen L et al Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis. Exp. Brain Res. 88(1), 117–130 (1992).
  • •This study gives evidence supporting the notion that modafinil may be neuroprotective.
  • Aguirre JA, Cintra A, Hillion J etal. A stereological study on the neuroprotective actions of acute modafinil treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral lesions of the male black mouse. Neumsci. Lett. 275(3), 215–218 (1999).
  • Antonelli T, Ferraro L, Hillion J, Tomasini MC, Rambert FA, Fuxe K. Modafinil prevents glutamate cytotoxicity in cultured cortical neurons. Neuroreport 9(18), 4209–4213 (1998).
  • •This study gives evidence supporting the notion that modafinil may be neuroprotective.
  • Rabinstein A, Shulman LM, Weiner WJ. Modafinil for the treatment of excessive daytime sleepiness in Parkinson's disease: a case report. Parkinsonism Relat. Disord 7(4), 287–288 (2001).
  • Rugino TA, Copley TC. Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study. J. A117. Acad. Child Adolesc. Psychiatry 40(2), 230–235 (2001).
  • Pack AT, Black JE, Schwartz JR, Matheson JK. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am. j Respir. Grit. Carr Med 164(9), 1675–1681 (2001).
  • Arnulf I, Homeyer P, Garma L, Whitelaw WA, Derenne JR Modafinil in obstructive sleep apnea-hypopnea syndrome: a pilot study in 6 patients. Respiration 64(2), 159–161 (1997).
  • Kingshott RN, Vennelle M, Coleman EL, Engleman HM, Mackay TW, Douglas NJ. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual excessive daytime sleepiness in the sleep apnea/hypopnea syndrome. Am. j Respir. Grit. Carr Med. 163(4), 918–923 (2001).
  • Heitmann J, Cassel W Grote L etal. Does short-term treatment with modafinil affect blood pressure in patients with obstructive sleep apnea? Clin. Phalmacol Ther 65(3), 328–335 (1999).
  • Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. j Clin. Rychiatry 61(5), 378–381 (2000).
  • DeBattista C, Solvason HB, Kendrick E, Schatzberg AE Modafinil as an adjunctive agent in the treatment of fatigue and hypersomnia associated with major depression. In: New Research Program and Abstracts of the 154th Annual Meeting of the American fiychiatric Association., May 9, 2001; New Orleans, LA, USA Abstract NR532,144 (2001).
  • Teitelman E. Off-label uses of modafinil. A117. Psych. 158(8), 1341–1342 (2001).
  • Saletu B, Saletu M, Grunberger J, Frey R, Anderer P, Mader R. Treatment of the alcoholic organic brain syndrome: double-blind, placebo-controlled clinical, psychometric and electroencephalographic mapping studies with modafinil. Neumpsychobiology27(1), 26–39 (1993).
  • Saletu B, Saletu M, Grunberger J, Frey R, Zatschek I, Mader R. On the treatment of the alcoholic organic brain syndrome with an alpha-adrenergic agonist modafinil: double-blind, placebo-controlled clinical, psychometric and neurophysiological studies. Pmg. Neuropsychopharmacol Biol Psychiatry 14(2), 195–214 (1990).
  • Breitbart W Rosenfeld B, Kaim M, Funesti-Esch J. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch. Intern. Med. 161(3), 411–420 (2001).
  • Olin J, Masand P Psychostimulants for depression in hospitalized cancer patients. Psychosomatics 37(1), 57–62 (1996).
  • Lazarus LW, Moberg PJ, Langsley PR, Lingam VR. Methylphenidate andnortriptyline in the treatment of poststroke depression: a retrospective comparison. Arch. Phis. Med. Rehabil 75(4), 403–406 (1994).
  • Masand P, Murray GB, Pickett P Psychostimulants in post-stroke depression. Neuropsychiatr Clin. Neurosci. 3(1), 23–27 (1991).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.